†Effects of varying base-case estimates on the incremental cost–effectiveness ratio of treating all patients with advanced renal insufficiency with an ACE inhibitor versus no ACE inhibitor treatment ...
Patients with heart failure who start taking sacubitril/valsartan (Entresto; Novartis) do not appear to have a greater risk of angioedema than do those who opt for an ACE inhibitor or ARB instead, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback